AstraZeneca's top products based on revenue 2016-2019
AstraZeneca is a global biopharmaceutical company with several leading pharmaceutical products. As of 2019, AstraZeneca’s top pharmaceutical product by revenue was Tagrisso, a medication used in the treatment of non-small-cell lung carcinomas. During that year, Tagrisso generated nearly 3.2 billion U.S. dollars in revenue for the company. The second-highest revenue generator for AstraZeneca in the same year was Symbicort, an inhaler used in the treatment of asthma and COPD. Symbicort generated about 2.5 billion U.S. dollars in revenue for the company during that year.
AstraZeneca company profile
AstraZeneca is a global pharmaceutical company with many employees all over the world. As of 2019, the highest proportion of AstraZeneca’s employees were based in the Asia-Pacific region. The global office and corporate headquarters of AstraZeneca is located in Cambridge in the United Kingdom. As of 2019, emerging markets and the U.S. market accounted for the highest revenues for AstraZeneca. The company is a leader in research and development globally as well.
AstraZeneca’s R&D
AstraZeneca has many research and development programs that are focused on addressing three main areas, oncology, cardiovascular, renal and metabolic diseases, and respiratory disease. AstraZeneca’s research and development expenditures have increased in recent years. In 2019, 25.7 percent of AstraZeneca’s total revenue was expended on research and development. And, as of early 2019, AstraZeneca was projected to be among the world’s top five pharmaceutical companies according to the number of drugs they had under development at that time.
AstraZeneca company profile
AstraZeneca is a global pharmaceutical company with many employees all over the world. As of 2019, the highest proportion of AstraZeneca’s employees were based in the Asia-Pacific region. The global office and corporate headquarters of AstraZeneca is located in Cambridge in the United Kingdom. As of 2019, emerging markets and the U.S. market accounted for the highest revenues for AstraZeneca. The company is a leader in research and development globally as well.
AstraZeneca’s R&D
AstraZeneca has many research and development programs that are focused on addressing three main areas, oncology, cardiovascular, renal and metabolic diseases, and respiratory disease. AstraZeneca’s research and development expenditures have increased in recent years. In 2019, 25.7 percent of AstraZeneca’s total revenue was expended on research and development. And, as of early 2019, AstraZeneca was projected to be among the world’s top five pharmaceutical companies according to the number of drugs they had under development at that time.
